Efficacy of long-term administration of high dosage betahistine in patients with unilateral peripheral vestibulopathy

Efficacy of long-term administration of high dosage betahistine in patients with unilateral peripheral vestibulopathy - Efficacy of long-term administration of high dosage betahistine in patients with unilateral peripheral vestibulopathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019016

Enrollment

150

Registered

2015-10-01

Start date

2015-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unilateral peripheral vestibulopathy

Interventions

Oral administration of high dosage of betahistine mesilate (72mg/day) for 3 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult (20-80 y/o) patients with unilateral peripheral vestibulopathy except Meniere's disease and benign paroxysmal positional vertigo, who complained of persistent dizziness for 3 months and have been successfully treated with short-term (4 weeks) administration of high dosage betahistine.

Exclusion criteria

Exclusion criteria: 1) Patients with peptic ulcer. 2) Patients with bronchial asthma. 3) Patients with pheochromocytoma. 4) Pregnant and breast-feeding female patinets 5) Patients who suffered from repetitive vertigo attacks 6) Patients who was excluded by investigators.

Design outcomes

Primary

Measure	Time frame
Dizziness Handicap Inventory score 4, 8, 12 weeks after intervention	—

Secondary

Measure	Time frame
Vestibular function	—

Countries

Japan

Contacts

Public ContactNoriaki Takeda

University of Tokushima School of Medicine Department of Otolaryngology

takeda@tokushima-u.ac.jp088-633-7169

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026